Loading …

ADmit Therapeutics is a biotech company focused on the commercialization of the MAP-AD® Test, an AI-powered prognostic test for Alzheimer’s disease with CE-IVDR certification. The company operates a CAP-accredited, CLIA-certified laboratory to offer the MAP-AD Test as an LDT in the US
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.